These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 10772999)

  • 1. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
    Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
    J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
    Staal RG; Sonsalla PK
    J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
    Brown JM; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1150-3. PubMed ID: 11504813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
    Brown JM; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neurotoxin 1-methyl-4-phenylpyridinium is a substrate for the canalicular organic cation/H+ exchanger.
    Moseley RH; Zugger LJ; Van Dyke RW
    J Pharmacol Exp Ther; 1997 Apr; 281(1):34-40. PubMed ID: 9103477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
    Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells.
    Chen CX; Huang SY; Zhang L; Liu YJ
    Neurobiol Dis; 2005 Aug; 19(3):419-26. PubMed ID: 16023584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of the neurotoxin, 4-methylphenylpyridinium, into chromaffin granules and synaptic vesicles: a proton gradient drives its uptake through monoamine transporter.
    Moriyama Y; Amakatsu K; Futai M
    Arch Biochem Biophys; 1993 Sep; 305(2):271-7. PubMed ID: 8373164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).
    Numis AL; Unger EL; Sheridan DL; Chisnell AC; Andrews AM
    Mol Pharmacol; 2004 Sep; 66(3):718-27. PubMed ID: 15322265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals.
    Nirenberg MJ; Chan J; Liu Y; Edwards RH; Pickel VM
    Synapse; 1997 Jun; 26(2):194-8. PubMed ID: 9131778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.
    Speciale SG; Liang CL; Sonsalla PK; Edwards RH; German DC
    Neuroscience; 1998 Jun; 84(4):1177-85. PubMed ID: 9578404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
    Giovanni A; Sonsalla PK; Heikkila RE
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Staal RG; Yang JM; Hait WN; Sonsalla PK
    Brain Res; 2001 Aug; 910(1-2):116-25. PubMed ID: 11489261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
    Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
    Neurotoxicology; 2004 Sep; 25(5):761-9. PubMed ID: 15288507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced MPTP neurotoxicity in striatum of the mutant mouse tottering.
    Kilbourn MR; Sherman P; Abbott LC
    Synapse; 1998 Oct; 30(2):205-10. PubMed ID: 9723790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.
    Cleren C; Naudin B; Costentin J
    Brain Res; 2003 Nov; 989(2):187-95. PubMed ID: 14556940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
    Teng L; Crooks PA; Dwoskin LP
    J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
    Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter.
    Pifl C; Hornykiewicz O; Giros B; Caron MG
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1437-43. PubMed ID: 8667208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.